article

Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets

Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.

THE HIGH-THROUGHPUT screening (HTS) landscape has seen significant changes over the past decade. Where previously large pharmaceutical companies had multiple HTS groups located at R&D sites across the world, the current model sees many with just a single global screening centre and, in some instances, HTS groups closed altogether in favour of outsourcing large-scale screening to contract research organisations (CROs). These changes have been driven by measures to improve efficiencies, company reorganisations and portfolio refocusing and has meant that in 2019, following GlaxoSmithKline’s closure of the Harlow site in 2010 and Pfizer’s exit of the Sandwich research facility in 2011, AstraZeneca (AZ) has the only remaining pharma HTS group in the UK. Prior to this, AZ had also reduced from four global screening sites in 2010 to a single HTS centre by 2012. Yet advances in drug discovery are dependent on identification of chemical starting points for discovery projects and HTS remains the cornerstone of this operation across the pharmaceutical industry.1-3











To read this article in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: BMG Labtech, ForteBio

One response to “Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets”

  1. Sherman LIU says:

    DEL will be a trend for new drugs development then HTS.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Send this to a friend